Your shopping cart is currently empty

ALK/HDAC-IN-1 is a dual inhibitor that targets both ALK and HDAC6, demonstrating IC50 values of 16 nM and 1.03 μM, respectively. This compound exhibits anti-tumor activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | ALK/HDAC-IN-1 is a dual inhibitor that targets both ALK and HDAC6, demonstrating IC50 values of 16 nM and 1.03 μM, respectively. This compound exhibits anti-tumor activity. |
| Targets&IC50 | HDAC6:1.03 μM, HDAC11:16.6 μM, HDAC8:1.69 μM, HDAC1:10.8 μM |
| In vitro | ALK/HDAC-IN-1 inhibits the proliferation of cancer cells A549, HepG2, MCF7, U87MG, and H2228 with IC50 values of 0.33, 0.59, 0.55, 0.62, and 0.44 μM, respectively. Additionally, ALK/HDAC-IN-1 inhibits the CYP450 enzyme CYP2C9, with an IC50 of 2.65 μM. |
| In vivo | ALK/HDAC-IN-1, administered at doses ranging from 0 to 20 mg/kg via intraperitoneal injection for 21 days, effectively suppresses tumor growth in A549 xenografts in BALB/c mice, with no significant toxicity observed. |
| Formula | C27H31N5O4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.